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Physical Intimacy of Breast Cancer
Cells with Mesenchymal Stem Cells
Elicits Trastuzumab Resistance
through Src Activation
Amita Daverey1, Allison P Drain1 & Srivatsan Kidambi1,2,3
The development of resistance to trastuzumab is a major obstacle for lasting effective treatment
of patients with ErbB2-overexpressing tumors. Here, we demonstrate that the physical contact of
breast cancer cells with mesenchymal stem cells (MSCs) is a potential modulator of trastuzumab
response by activation of nonreceptor tyrosine kinase c-Src and down regulation of phosphatase
and tensin homolog (PTEN). Using an in vitro patterned breast cancer/MSC co-culture model, we
find that the presence of MSCs results in Src activation that is missing in cancer cells monoculture,
transwell co-culture, and cells treated with MSCs conditioned media. Interestingly, the co-culture
model also results in PTEN loss and activation of PI3K/AKT pathway that has been demonstrated as
fundamental proliferative and survival pathways in clinical settings. To our knowledge, this is the first
report that showed PTEN loss without the use of chemical inhibitors, matrix stiffness, or silencing
RNAs. In addition, breast cancer cells in co-culture with MSCs conferred trastuzumab resistance in
vitro as observed in the lack of inhibition of proliferative and migrative properties of the cancer cells.
Our findings show that MSCs are potent mediators of resistance to trastuzumab and might reveal
targets to enhance trastuzumab efficacy in patients.

Human epidermal growth factor receptor-2 (HER-2 or ErbB2) gene is overexpressed in approximately
20–25% of human breast cancers and is associated with poor clinical prognosis and survival1,2. Treatment
with trastuzumab, a humanized antibody that targets HER-2, has dramatically altered the course of HER-2
positive breast cancer patients. However, majority of the patients do not respond to initial treatment or
develop resistance after continuous treatment of the drug3,4. Two major trastuzumab resistance mechanisms have been proposed: (i) de novo resistance due to genetic alterations of receptor tyrosine kinases
(RTKs) and their downstream signaling targets (such as phosphatase and tensin homolog (PTEN) loss
and activation of the phosphoinositide 3-kinase (PI3K)); and (ii) acquired resistance primarily due to
the acquisition of alternative RTK signaling activation that compensate for HER-2 inhibition after trastuzumab treatment3–5. Recent studies have highlighted a new resistance mechanism implicating nonreceptor tyrosine kinase c-Src as a key modulator of trastuzumab response and a common node downstream
of multiple trastuzumab- resistance pathways6–8. Increased activation of Src has been observed in both
acquired and de novo trastuzumab-resistant cells and this activation regulates the loss of PTEN, thus
promoting drug resistance. Moreover, in vitro and in vivo experimental results strongly indicate an
important role of Src in the development and progression of breast cancer as well as a viable therapeutic
option6–8. Despite these promising experimental data, the underlying molecular mechanisms of what
might activate Src leading to trastuzumab resistance remains unclear.
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Tumor microenvironment has garnered the spotlight in recent years for its important role in tumor
progression and drug resistance9–11. Tumors actively modulate their microenvironment by recruiting
lymphocytes and macrophages12; vascular endothelial cells; and tumor-associated stromal cells such
as tumor-associated fibroblasts (TAFs) and mesenchymal stem cells (MSCs)13,14. MSCs, in addition to
other cells in the tumor microenvironment, have been identified as an important population of cells
that modulate tumor progression and drug sensitivity15–17. Recent reports have demonstrated that MSCs
are recruited in large numbers to the stroma of developing tumors18,19. Furthermore, MSCs integrate
into tumor-associated stroma, and exhibit multiple regulatory functions in the tumor microenvironment13,20,21. The bidirectional paracrine signaling between MSCs and breast cancer cells are found to
stimulate tumor growth, enhance angiogenesis, and promote metastasis formation through the release
of a large spectrum of growth factors and cytokines22–24. MSCs also promote tumor cell migration, an
epithelial-to-mesenchymal transition (EMT), and increase chemoresistance in breast cancer cells15–17.
Growth patterns of cancer cells in co-culture change from a clustered to a single cell distribution, and
these morphological alterations have been related to a significant down regulation of cell adhesion molecules E-cadherin and epithelial specific antigen (ESA)25. MSCs are also believed to modulate the response
to drugs including trastuzumab by either direct cell-cell interactions with tumor cells, or by the local
release of soluble factors such as interleukin-6, promoting survival and tumor growth15,26–28.
The growth- and metastasis-promoting effects of MSCs have been well documented22–24, but a possible role in drug resistance including activation of Src and downstream pathways has been only partially
explored, and has been difficult to obtain. This is due, in part, to the complexity of recreating and isolating the cell-cell communications in clinical and in vivo models. Advances in humanized mouse models
have closed this gap; however, the heterogeneity of the human xenografts grafted into the mouse models
makes it challenging to study cell-cell communication in tumors. Primary human breast cancer cells have
contributed to the advancement of our understanding of cancer biology, however, this system cannot
evaluate interactions between carcinoma and intratumoral stromal cells. Co-culture compositions of two
different cell type of cancer tissues i.e., breast cancer cells and stromal cells, were established in order
to evaluate cell–cell interactions in tumor microenvironment. However, the use of random co-culture
does not recreate the physiologically relevant interactions. Indirect co-culture method using transwell
inserts provide valuable information on the role of secreted factors but the physical contact between the
cells present in physiological conditions is missing. We and others have developed in vitro co-culture
systems capable of engineering controlled environment of spatially defined micro-scale surfaces using
microfabrication techniques29–33. This system provides an ideal platform to study the role of cell-cell
communication on critical tissue function. In this study, we hypothesize that Src mediated trastuzumab
resistance might be caused, at least in part, by cell-cell communication between MSCs and tumor cells,
where in physical intimacy between the cells is the key factor. To test this hypothesis, we developed a
co-culture system whereby HER-2 positive tumor cells are co-cultured with MSCs, and the ability of the
MSCs to activate Src and modulate downstream drug resistance pathways is observed.

Results

Physical Contact of MSCs with Breast Cancer Cells Activates Src.

To test the hypothesis that
physical intimacy and not soluble factors from MSCs activates Src, we established four different systems
to recreate these interactions. Human breast cancer cells were cultured 1) alone (monoculture); 2) treated
with conditioned media from MSCs (MSCs-CM) to introduce secreted soluble factors into breast cancer cells; 3) co-culture of breast cancer cells with MSCs using transwell (Boyden Chamber) to monitor
cell-cell interactions through soluble factors derived from each cells and 4) random co-culture with
MSCs which contains the physical contact and ability to share soluble signaling factors (co-culture). We
employed two developmentally distinct human breast cell lines for this study: 1) BT474 (HER2+ invasive
breast cancer cells), and 2) 21MT-1 (stable patient-derived metastatic breast cancer cells isolated from
the metastatic pleural effusion). We specifically chose 21MT-1 cells due to recent reports highlighting the
21T cell line’s ability to mimic in vivo cancer development and behavior within the in vitro enviroment
through stage specific cell proliferation, migration, morpholgy, polarization, and gene expression profiles,
and its consequent potential for usage as a valuable translational disease model for breast cancer34. A significant (p <  0.01) increase in Src protein expression was observed in random co-cultures of breast cancer cells and MSCs, while no significant change (p >  0.05) was observed in cells exposed to MSCs-CM,
transwell co-culture, and monoculture of breast cancer cells (Fig. 1). Furthermore, no significant increase
in Src expression was observed in breast cancer cells co-cultured with MCF10A cells (mammary epithelial cells), suggesting that this is a MSC-specific phenomena (Supplementary Fig. 1). This data suggest
that the physical contact of breast cancer cells with MSCs is critical for MSCs mediated regulation of Src,
and one of the possible mechanisms for Src activation in aggressive breast cancers.

Establishing Patterned Co-culture of Breast Cancer Cells and MSCs.

To further investigate the
effect of interaction of MSCs with breast cancer cells, we established a patterned co-culture system of
breast cancer cells with MSCs using polyelectrolyte multilayer (PEM) films. We have previously screened
several polymers similar to self-assemble protein network found in extracellular matrix35. Among all polymers, poly(diallyldimethylammonium chloride) (PDAC) and poly(4-styrenesulfonic acid) (SPS) were
selected due to their ability to produce most consistent observations with cell attachment (Fig. 2A). For
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Figure 1. Physical contact of MSCs with breast cancer cells activates Src. (a) Upper panel shows
representative immunoblots of Src detected in BT-474 and 21MT-1 cells co-cultured with MSCs, transwell
co-culture or MSCs-CM. (b) Lower panel shows respective densitometry of bands; monocultures of BT474 and 21MT-1 were used as control. Asterisks represent statistical significant differences in change in
expression of Src in co-cultures samples compared with monoculture control. Data are mean ±  SD; n =  3
independent experiments; **p <  0.01 compared with control.

all experiments, 10 or 10.5 bilayers of PDAC/SPS were deposited on tissue culture polystyrene surfaces
(TCPS) making SPS or PDAC as topmost layer and are designated as (PDAC/SPS)10 or (PDAC/SPS)10.5
respectively. No difference in morphology and growth of BT-474, 21MT-1 and MSCs were observed
when cells were grown on (PDAC/SPS)10 compared to control. Quantitative analysis of attachment of
cells on PEM films indicated higher attachment on (PDAC/SPS)10 compared to (PDAC/SPS)10.5 (Fig. 2A
and Supplementary Fig. 2). The specific protein markers for breast cancer cells (HER-2 expression) and
for MSCs (CD166) remained unchanged on both polymer surfaces compared to control, suggesting that
polymer surfaces do not influence the biology of the cells beyond the cell adhesion behavior (Fig. 2B).
The approach for developing the patterned co-culture of breast cancer cells and MSCs consisted of
capitalizing upon the cell adhesive and resistive property of SPS and PDAC, respectively, as shown in
Fig. 2C and Supplementary 3. Unlike random co-culture where interaction of two cells is difficult to control, patterned co-culture provides a highly controlled system where cell placement and precise cell-cell
interaction can be tuned by varying size and shape of patterns on fabricated surfaces. Patterns were fully
characterized before seeding cells on fabricated surfaces using negatively charged fluorescent dye and
polystyrene carboxylate microparticles (data not shown). Breast cancer cells preferentially attached on
the SPS patterns when they were seeded on the PEM surfaces (Fig. 2C). MSCs were subsequently seeded
onto the patterns of breast cancer cells thus engineering patterned co-cultures of breast cancer cells and
MSCs (Fig. 2C). We also measured the average percent coverage of breast cancer cells and MSCs in
15 different patterns that demonstrated consistent patterning technique and development of patterned
co-culture of breast cancer cells with MSCs (Supplementary Fig. 4).

MSCs induce Src Activation in Patterned Co-culture and not in Conditioned Media. Given

our observation that MSCs induce Src activation in random co-culture, we tested that phenomenon in
our patterned co-culture system as well. To investigate this, we probed breast cancer cells and MSCs
using antibodies against Src (red) and CD166 (green) (Fig. 3A). Akin to random co-culture, breast cancer
cells in co-culture with MSCs indicated higher Src expression compared to monoculture and breast cancer cells exposed to conditioned media from MSCs (MSCs-CM) (Fig. 3A, upper panel). Quantification
of fluorescence intensity shows that the Src expression in co-cultures increased ∼ 2 fold compared to
the monoculture (Fig. 3A, lower panel). In co-culture, MSCs also show Src expression, however, merge
images indicated that majority of the Src fluorescence is from the breast cancer cells.
To further investigate how physical contact of MSCs regulates Src activation in breast cancer cells,
we examined whether MSCs in co-culture with breast cancer cells may activate Src tyrosine kinase.
To quantify the Src expression in breast cancer cells, we sorted the co-culture cells using fluorescence
activated cell sorting (FACS) by pre-staining the breast cancer cells and MSCs with red and green dye
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Figure 2. Establishing patterned co-culture of breast cancer cells and MSCs. (a) Left, optical micrographs
of breast cancer cells and MSCs cultured on various surfaces after 5 days (Scale bar, 500 μ m); Right,
quantitative analysis of attachment of cells determined with MTT assay. Cells grown on TCPS were
used as control. Mean ±  SD; n =  3 independent experiments; **p <  0.01 compared with control. (b) Left,
immunoblots show protein expression of specific markers of BT-474, 21MT-1 and MSCs on different
surfaces. Right, respective densitometry of bands normalized with control after loading control (GAPDH)
correction. Cells grown on TCPS served as control. (c) Scheme illustrating the approach for engineering
patterned co-culture of breast cancer cells and MSCs (The scheme is not drawn to represent the true nature
of the co-culture system) Fluorescent images of patterned monocultures of BT-474 and 21MT-1 (green) and
patterned co-culture of breast cancer cells (green) and MSCs (red) after seeding MSCs (Scale bars- 200 μ m).
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Figure 3. MSCs induces Src activation in patterned co-culture and not in conditioned media. (a)
Immunostaining of Src (FITC, green) and MSCs marker- CD166 (Cy3, red) in (i) patterned monoculture
of breast cancer cells; (ii) Breast cancer cells exposed to MSCs-CM; (iii) patterned co-culture of breast
cancer cells with MSCs; (iv) enlarged image of (iii). (b) Upper panel, immunobots show activation of Src
in breast cancer cells sorted after co-culture with MSCs using FACS, and in breast cancer cells exposed to
MSCs-CM and in transwell co-culture. Lower panel, quantification of band intensity to assess the relative
phosphorylation of Src at tyrosine 416 position (Y416). Mean ±  SD; n =  3 independent experiments;
*p <  0.05 compared with monoculture; **p <  0.01 compared with monoculture.

prior to co-culture. Src expression in FACS sorted cells was examined using western blotting. To validate the efficiency of FACS, the sorted cells were probed with breast cancer specific marker HER-2,
and MSCs specific marker, CD166. Results indicated that the HER-2 expression and CD166 expression
were observed only in sorted breast cancer cells and sorted MSCs, respectively (Supplementary Fig. 5).
Compared to monoculture, transwell co-culture, and MSCs conditioned media treated breast cancer
cells, patterned co-culture significantly (p <  0.05 and p <  0.01) increased Src phosphorylation at Y416
(Src-pY416) (Fig. 3B and Supplementary Fig. 5), an indicator of Src activity6,7,36. Together, our data indicate that physical contact of MSCs with breast cancer cells activates Src kinase activity in HER-2 overexpressing breast cancer cells, and this is not observed in breast cancer cells in mono-culture, transwell
co-culture, or those treated with conditioned media from MSCs.

MSCs Activates Pathways Regulating Tumor Growth and Trastuzumab Resistance. Src
activation has been demonstrated to play a direct role in the progression of aggressive HER-2 positive
breast cancer6,7. To explore the effect of MSCs on tumor growth, we examined whether MSCs in contact
with tumor cells has any effect on HER-2 expression, an important biomarker and indicator of tumor
growth and progression1,2. Immunostaining of HER-2 demonstrated increased fluorescence in patterned
co-culture as compared to the monoculture and cancer cells exposed to MSC conditioned media (Fig. 4A
Scientific Reports | 5:13744 | DOI: 10.1038/srep13744
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Figure 4. For legend see next page.

and Supplementary Fig. 4). Quantification of fluorescence intensity indicated higher HER-2 expression
in breast cancer cells in co-culture compared to both monoculture and breast cancer cells exposed to
MSCs-CM. To further confirm that MSCs mediated Src activation regulate HER-2, we examined the
Scientific Reports | 5:13744 | DOI: 10.1038/srep13744
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Figure 4. MSCs activates pathways regulating tumor growth and trastuzumab resistance. (a) Left,
Immunostaining of HER-2 (Texas red) to assess the expression of HER-2 in patterned co-culture. Right,
quantification of fluorescence intensity of HER-2 expression using imageJ. Mean ±  SD; n =  3 independent
experiments; **p <  0.01 compared with monoculture; ***p <  0.001 compared with monoculture. (b)
Top, immunoblots of HER-2 expression in BT-474 and 21MT-1 cells sorted after co-culture with MSCs,
and after exposed to MSCs-CM. Bottom, respective densitometry of HER-2 expression normalized with
monoculture after GAPDH correction. Mean ±  SD; n =  3 independent experiments; **p <  0.01 compared
with monoculture. (c) Top, immunoblots of PTEN expression in BT-474 and 21MT-1 cells sorted after coculture with MSCs, transwell co-culture and after exposed to MSCs-CM. Bottom, respective densitometry
of PTEN expression normalized with monoculture after GAPDH correction. Mean ±  SD; n =  3 independent
experiments; **p <  0.01 compared with monoculture. (d) Top, western blot analysis of PI3K, pAKT
and AKT. Bottom, respective densitometry of bands normalized with monoculture after loading control
(GAPDH) correction. Expression of pAKT was further normalized with AKT (pAKT/AKT). Data are
mean ±  SD; n =  3 independent experiments; *p <  0.05 compared with monoculture; **p <  0.01 compared
with monoculture.

protein expression in breast cancer cells after co-culture using western blotting (Fig. 4B). A notably
increased HER-2 expression in both BT-474 and 21MT-1 cells were observed in co-culture with MSCs
compared to monoculture and MSCs-CM treated cells. Also, upregulation of HER-2 expression was more
prominent in 21MT-1 cells, which are derived from metastatic cancer patients, suggesting the potential
role of MSCs in more aggressive tumors.
To investigate how MSCs mediated activation of Src regulates phosphatase and tension homolog
(PTEN), we examined whether breast cancer cells in co-culture with MSCs may inhibit PTEN, since
Src activation has recently been reported to promote loss of PTEN8. We observed reduced expression
of PTEN in BT-474 and complete loss of PTEN in 21MT-1 cells in co-culture with MSCs. In contrast,
no change was observed in BT-474 cells exposed to MSCs-CM or in transwell co-culture, however, substantial downregulation was observed in 21MT-1 cells exposed to MSCs-CM and in transwell co-culture
(Fig. 4C and Supplementary Fig. 5). This suggests that PTEN loss is not limited to the physical contact
of MSCs with breast cancer cells in more aggressive cancers. This data is significant; as for the first
time a PTEN deficient breast cancer in vitro model has been generated without the use of chemical
inhibitors37,38, matrix stiffness39, or silencing RNAs40,41, thus indicating that our co-culture model is a
physiologically relevant model. PTEN is a well-known tumor suppressor, and loss of PTEN has long
been associated with tumor progression and drug resistance42. Furthermore, several reports in different tumor models have shown that PI3K/Akt signaling pathways become fundamental proliferative and
survival pathways under PTEN loss or Src activation8,43. Thus, we investigated if physical contact of
breast cancer cells with MSCs regulates these pathways. In our experimental settings, we observed ~2
fold increase in PI3K expression in BT-474 cells and ~3 fold increase in 21MT-1 cells when co-cultured
with MSCs (Fig. 4D). Correspondingly, we observed activation of AKT by phosphorylation at serine
473 (AKT-pS473) in BT-474 as well as in 21MT-1. Significant increase (p <  0.01) in total AKT was also
observed in BT-474 exposed to MSCs, in contrast no change in total AKT was observed in 21MT-1.
Notably, no significant changes were observed in BT-474 and 21MT-1 cells exposed to MSCs-CM. These
data are indicative of the role of MSCs mediated regulation of the proliferative and survival pathways of
breast cancer cells where Src is activated and/or HER-2 is upregulated.

Breast Cancer Cells in Co-culture with MSCs Contribute to Trastuzumab Resistance. To
investigate if the physical intimacy of MSCs may confer resistance to trastuzumab in breast cancer cells,
we assessed the migratory potential of cancer cells in co-culture when exposed to the drug. Trastuzumab
has been shown to inhibit cell migration in both in vitro and in vivo studies, however the drug loses this
ability in drug resistant tumors3. In order to evaluate the effect of direct contact of MSC on breast cancer
cells migration, we probed the migration capacity of BT-474 and 21MT-1 in mono-cultures, exposed
with MSCs-CM, and co-cultures with MSCs in the presence of trastuzumab (Fig. 5A). A scratch was
made in a sub-confluent cell monolayer and cells were allowed to migrate into the cell-free area. The
distance moved by the cells in control, MSC-CM treated cells, and co-cultured plates, respectively, was
compared when exposed to the drug. To distinguish the cell populations, breast cancer cells and MSCs
were stained with green dye, CFDSE and red dye, PKH26 respectively. In the absence of trastuzumab,
the co-culture of BT-474 and 21MT-1 cells with MSCs showed significantly (p <  0.001) higher migration
after 48 h of co-culture as compared to the respective monocultures. On the other hand, only 21MT-1
cells treated with MSCs-CM demonstrated significant migration as compared to monoculture (p <  0.05).
When BT-474 mono-culture cells were exposed to Ttzm, there was no significant change in the migratory property in mono-culture and MSCs-CM conditions but BT-474 in co-culture showed significantly
(p <  0.01) higher migration when compared to untreated co-culture samples. In contrast, when 21MT-1
mono-culture and MSC-CMs cells were exposed to Ttzm, there was no significant no signficiant inhibition in the migratory potential while 21MT-1 in co-culture showed significantly (p <  0.05) even after
exposed to Ttzm. This data suggest that direct interaction of MSCs with breast cancer cells promotes
Scientific Reports | 5:13744 | DOI: 10.1038/srep13744
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Figure 5. Breast cancer cells in co-culture with MSCs contribute to trastuzumab resistance. (a) Migration
assay data detailing the migration of cells out from a confluent monolayer onto a featureless scratch or
wound. Left, representative fluorescent images of breast cancer cells (CFDSE, green) and breast cancer cells
co-cultured with MSCs (PKH26, red) before and after treatment with trastuzumab (Ttzm) at time =  0 h
and 48 h. Scale bar 500 μ m. Right, quantification of wound closure. The percentage of wound closure was
determined by using following equation: % wound closure =   [(Area @ t =  0–Area @ t =  48)/Area @
t =  0h]×  100%. Data are mean ±  SD; n =  3 independent experiments; **p <  0.01 compared with untreated
monoculture; ***p <  0.001 compared untreated monoculture; ^^p <  0.05 compared with random coculture; ^p <  0.01 compared with random co-culture. (b) MSCs in co-culture with breast cancer cells
confer trastuzumab resistance. Left, western blot analysis of Ki67 in breast cancer cells sorted by FACS after
co-culture with MSCs, and breast cancer cells exposed to MSCs-CM in the presence or absence of Ttzm.
Right, respective densitometry of bands normalized with respective untreated group after loading control
(GAPDH) correction. Mean ±  SD; n =  3 independent experiments; *p <  0.05 compared with untreated
monoculture. (c) Suggested model of trastuzumab resistance mediated by MSCs via activation of Src. Figure
drawn by Dr. Amita Daverey.
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migration of breast cancer cells and potentially regulates the Ttzm responsiveness in breast tumor cells
when in physical contact.
In the light of this data, we further validated the effect of MSCs-breast cancer cells interaction on
trastuzumab resistance by determining Ki67, a clinical maker for the rate of proliferation in breast cancer
cells and key hallmark of trastuzumab mechanism of action (Fig. 5B and Supplementary Fig. 6). Breast
cancer cells were cultured as monocultures, co-cultures with MSCs, and MSC-CM treated groups in the
presence or absence of trastuzumab for 48 h. Breast cancer cells in the co-culture system were separated
using FACS and probed for Ki67, a proliferation marker. The Ki67 expression decreased significantly
(p <  0.05) in BT-474 and 21MT-1 monocultures after trastuzumab treatment compared to untreated
monocultures. However, no change in Ki67 expression was observed in BT-474 and 21MT-1 co-cultured
with MSCs after trastuzumab treatment, thus indicating that the tumor cells are unresponsive to the
drug. Interestingly, no significant effect was observed in Ki67 expression when BT-474 exposed to
MSCs-CM treated with Ttzm but 21MT-1 exposed to MSCs-CM treated with Ttzm indicated decreased
Ki67 expression. The differential behavior between Bt-474 and 21MT-1 might potentially be due to the
different sources of the tumor cells, which needs further investigation.

Discussion

Trastuzumab is a highly specific, targeted cancer therapy that has brought valuable therapeutic benefits
to HER-2-overexpressing cancer patients44. However, the limited response and drug resistance, even in
patients with tumors expressing very high levels of HER-2, raises questions on the mechanisms of trastuzumab resistance in patients. The possible mechanisms that contribute to the frequent development
of resistance to trastuzumab are at its infant stages, and are an active area of investigation4,8. Recent
studies have demonstrated that activation of Src is important during development of trastuzumab resistance. Here, we report that the breast cancer cell in physical contact with MSCs elicit Src activation and
regulates downstream trastuzumab resistance pathways (Fig. 5C). We developed a co-culture model to
study the interaction between MSCs and breast cancer cells, and identified previously unexplored regulation of Src through MSCs in HER-2 positive breast cancer cells. The unique patterned co-culture
model enables us to recreate the cell-cell communication underway in tumor development and progression. The model provides the ability to capture the temporal changes in the cell biology as the tumor
develops through various stages. The significant advantages of our patterned co-cultures are: (1) the
protein-free cell-culture environment reduces nonspecific function; (2) provides ease of visualization,
patterned co-culture platform has several advantages over random co-cultures; (3) precise and consistent
control of degree of contact between the cells (demonstrated in Supplementary Figure 4); and (4) the
cancer cell-MSC interaction can be controlled by varying the percent coverage of the cells using different
pattern dimensions to emulate different stages of a breast tumor. To validate the physiological relevance
of this study, we used patient-derived HER-2 positive metastatic breast cancer cells (21MT-1) isolated
from the metastatic pleural effusion. This finding led to the new concept that physical contact of MSCs
is a key factor that contributes to trastuzumab’s resistance by activating Src. We also found that MSCs
presence causes overexpression of HER-2 and loss of PTEN. This indicates that MSCs regulates the
functional crosstalk between the HER-2 receptor and the PTEN tumor suppressor in breast cancer cells
via Src. Src plays important oncogenic functions (e.g., inactivates PTEN) when bound to and activated
by overexpressed HER-2, which contributes to the trastuzumab resistance. To our knowledge, no study
has specifically investigated the role of MSCs in regulation of Src in breast cancer, which has been shown
as common node for multiple pathways associated with growth, invasion and trastuzumab resistance of
this disease.
In vitro and in vivo studies have demonstrated the role of Src in cellular growth and proliferation,
angiogenesis, invasion and metastasis. The elevated expression of Src has been previously reported in
majority of breast cancer tissues which is significantly associated with HER-2 status and metastatic disease6,7,45. Belsches-Jablonski et al. identified stable complex formation between Src and HER-2 in 13 breast
cancer cell lines46. On the other hand role of MSCs on breast cancer progression remain unclear and
controversial. It has been reported that bone marrow derived human MSCs can stimulate MCF-7 breast
cancer cell proliferation in vitro and promote breast tumor metastasis in a xenograft model15–17. Recently,
Clarke et al. showed the inhibition of migration and invasion in breast cancer cells, MDA-MB-231 and
T47D, through immortalized MSC line RCB215747. Of note, they used co-cultured breast cancer cells in
a transwell insert above MSCs or MSCs conditioned media, therefore, results obtained here are mediated only through soluble factors. However, there are several reports that show that MSCs inhibited
the growth of tumors in xenograft breast cancer model when co-inoculated with human cancer cells or
administered intravenously to animals48,49. In contrast, Usha et al. documented that MSCs do not promote or inhibit the tumor growth and development in a clinically relevant mouse model50. We observed
MSCs resulted in the overexpression of HER-2 expression in breast cancer cells in our co-culture model,
however conditioned media or transwell co-culture did not have any effect on the HER-2 expression.
This observation is corresponding to the Src activation, thus, increased expression of HER-2 and Src may
have direct interaction which results in promoting the growth of breast cancer cells. Our study showed
increased proliferation of breast cancer cells in co-culture systems as evident by increased expression of
Ki67. Therefore, from our study and previous reports it is evident that the outcome of MSCs on tumor
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growth and progression is dependent on the tumor types, the sources of MSCs and mouse models such
as syngeneic versus xenogeneic graft.
Several studies based on pharmacological inhibitors of Src family tyrosine kinases indicate that Src
activation is upstream of PI3K. In addition, PI3K has been shown to be a preferential substrate for Src
and a major signaling hub downstream of HER-2. We demonstrated that activation of Src at Tyr416 not
only activates AKT (Ser473) but also increased the activity of PI3K in breast cancer cells co-cultured
with MSCs. In support to our findings, recent report has reported the activation of PI3K/AKT signaling pathways mediated by Src activation in trastuzumab resistant breast cancer cells8. In addition, their
data showed that increased Src phosphorylation at Tyr416 regulates the loss of PTEN. Interestingly, we
observed PTEN loss in highly metastatic cell line 21MT-1 mediated through physical contact of MSCs
with breast cancer cells as well as through soluble factors alone. In contrast, PTEN loss observed in
BT-474 cells was primarily due to result of physical contact of MSCs with breast cancer cells. In contrast, Dasari et al. observed that the MSCs are able to upregulate PTEN simultaneously downregulating
the PI3K/Akt pathway51. However, these studies were carried out on glioblastoma and human umbilical
cord blood-derived MSCs which have possibly have a different synergistic pathway compared to breast
tumors. To our knowledge, this is the first report that showed PTEN loss by MSCs in breast cancer cells
without the use of chemical inhibitors37,38, matrix stiffness39, or silencing RNAs40,41. Since Src Tyr416
served as a direct substrate for PTEN loss, it is possible that MSCs activates Src via knocking down the
PTEN. However, we did not observe activation of Src in 21MT-1 through conditioned media or transwell co-culture, thus, whether MSCs regulate Src independently or through PTEN loss remains to be
explored. Earlier studies showed that loss of PTEN, Src activation and increased activity of PI3K/AKT
pathways confer trastuzumab resistance to breast cancer cells8,42. In support of these studies, our wound
healing data indicate that breast cancer cells harbor resistant to trastuzumab therapy in the presence of
MSCs which was further confirmed by increased proliferation of breast cancer cells in co-cultures as
compared to mono-culture systems.
In summary, our study identifies a systemic mechanism of resistance via interaction of breast cancer
cells with MSCs by activation of Src and its downstream PI3K/AKT pathways. We have provided evidence that the physical contact is important for breast cancer cells to develop drug resistance and enhance
tumor growth, metastasis and drug resistance. To validate the physiological relevance of this study, we
used patient-derived HER2+ metastatic breast cancer cells (21MT1) isolated from the metastatic pleural
effusion. Our findings introduce important players to the field of drug resistance, and indicate targeting
physical interaction of MSCs and breast cancer cells might be a possible strategy for drug resistant HER-2
positive breast tumors. It should be noted that the MSC-mediated Src activation and trastuzumab resistance mechanism detailed here is potentially one of the many possible tumor microenvironment-mediated
drug resistance interactions. Our findings point to the tumor microenvironment as an important but
understudied source of anticancer drug resistance. Moreover, the results suggest that such resistance
mechanisms can be uncovered through the systematic dissection of interactions between tumors and
their microenvironment. Future studies should therefore seek to identify such resistance mechanisms for
all of the drugs that are in development, potentially leading to mechanism-based combination regimens
to overcome drug resistance.

Materials and Methods

HER-2 overexpressed breast cancer cell lines, BT-474 and 21MT-1 were kindly provided by Drs. Hamid
Band and Vimla Band (UNMC, USA). Adipose derived MSCs were obtained from American Type Culture
Collection (ATCC). BT-474 cells were grown in complete α -MEM made up of α -MEM medium supplemented with 5% FBS, 1% L-glutamine, 100 U/mL penicillin G, 100 μ g/mL streptomycin, 20 mM HEPES,
non-essential amino acids and sodium-pyruvate (complete α -MEM). 21MT-1 cells were developed by
Dr. Vimla Band from a metastatic breast cancer patient and maintained in complete α -MEM, further
supplemented with 12.5 ng/ml epidermal growth factor (EGF) and 1 ng/ml hydrocortisone. MSCs were
grown in MSCGM (Lonza) supplemented with growth factors provided with kit. For all experiments
MSCs were not used more than 3 passages. All cells were grown in the presence of 5% CO2 at 37 °C.
Two co-culture systems were utilized: (1) direct co-culture (random or patterned co-culture), (2)
indirect co-culture (conditioned media from MSCs or transwell co-culture). For random co-culture,
0.3 ×  106 BCCs were seeded into per well of 6 well plate followed by seeding 0.1 ×  106 MSCs on Day 2.
BCCs were allowed to grow for 72 h in the presence of MSCs. For patterned co-culture, 0.6 ×  106 BCCs
were first seeded into per well of fabricated 6-well plate and allowed to grow for two days. After that,
0.2 ×  106 MSCs were added on day 2, cells were were allowed to grow for 72 h in co-culture. For conditioned media (MSCs-CM) experiments, 0.5 ×  106 MSCs were seeded into 60 mm petri dish and allowed
to grow for 2 days. Conditioned media was collected from 80% confluent monolayer at passage 3 on Day
2, and store at − 80 °C until use. MSCs-CM was added to the BCCs cultures on day 2 and allowed to
expose to the MSCs-CM for 72 h. For transwell experiments, 30,000 BCCs per well were first seeded on
the bottom of 24-well transwell cell culture system (Pore size 0.4 μ m; Costar Corp, USA) and allowed to
grow for two days. On day 2, transwell insert were placed into wells of BCCs cultures, and 10,000 MSCs
per well were seeded onto the membrane of transwell cell culture inserts. The cultures were allowed to
grow for 72 h. For all co-culture systems, medium of BCCs was exchanged with co-culture media (1:1
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ratio of BCCs medium and MSCs medium) on day 2. For all experiments monoculture of BCCs grown
in co-culture media was used as control.

Wound healing assay. Cells were seeded as monocultures and co-cultures in a 6 well plate as
described earlier in “co-culture” section. Cells were allowed to grow under permissive conditions until
80% confluence and a wound was created using a sterile 10 μ l pipette tip. The wounded cells were washed
three times with PBS to remove detached cells and the cells were incubated in co-culture media in the
presence or absence of 20 μ g/ml trastuzumab, a kind gift from Genentech (South San Francisco, CA). The
wound area at 0, 24 and 48 h after scratching was photographed using a microscopy system (Axiovert40
Zeiss, Germany), and the cell-free wound area was measured using NIH Image J software. The percentage of wound closure was determined by using following equation:
% of wound closure =  [(Area @ t =  0–Area @ t =  48)/Area @ t =  0h] ×  100%
Statistics.

Statistical analysis were made using GraphPad Instat 5.0 program (GraphPad Software,
USA). Comaprison between each groups were determined using nonparametric One-Way-ANOVA and
Student-Newman-Keuls Multiple Comparisons Test. Each value represents mean ±  sd from minimum
3 biological replicates. Statistical significance between two samples was determined by a P value of less
than 0.05. P values of less than 0.05, 0.01, or 0.001 are described as *P <  0.05, **P <  0.01, or ***P <  0.001,
respectively.
Please refer to SI Materials and Methods for detailed methods.
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